<DOC>
	<DOCNO>NCT01703455</DOCNO>
	<brief_summary>This single agent , prospective , open-label , monocenter , phase II trial sorafenib patient recurrent and/or metastatic salivary gland carcinoma . This trial conduct primary aim determine response rate ( CR+PR ) accord RECIST criterion . Response rate accord CHOI criterion , correlation CHOI criterion outcome , disease Control Rate ( DCR ) acute toxicity evaluate secondary objective .</brief_summary>
	<brief_title>Activity Sorafenib Salivary Gland Cancer</brief_title>
	<detailed_description />
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Histologically proven relapse and/or metastatic salivary gland cancer potentially curative option surgery radiotherapy indicate One target lesion measurable CTscan MRI accord RECIST criterion Age + 18 year ECOG 0 1 Adequate bone marrow , liver renal function Signed write informed consent Symptomatic metastatic brain meningeal tumor History cardiac disease congestive heart failure &gt; NYHA class 2 Active CAD Cardiac arrhythmia require antiarrhythmic therapy uncontrolled hypertension Pregnant breastfeeding patient Patients evidence history bleed diathesis Patients undergoing renal dialysis Patients unable swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Salivary gland cancer metastatic disease recurrent disease clinical trial</keyword>
</DOC>